High Court Restrains Glenmark Pharmaceuticals from Business of Anti-Diabetes Drugs

nDimensionsIP
Oct 24, 2015
1 min read

In a relief for US drug major Merck Sharp and Dohme (MSD), Delhi High Court restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, saying it has infringed patent of the American company.

#GlenmarkPharmaceuticals

Recent Posts

See All

General Motors gets Indian patent related to powertrain technology

General Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...

Trademarks Office: Abandonment orders kept in abeyance

Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...

Delhi High Court: No “irreconcilable conflict” between the Competition Act and the Patents Act

The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...

nDimensions IP

High Court Restrains Glenmark Pharmaceuticals from Business of Anti-Diabetes Drugs

Recent Posts

Comments

Working Hours

Contact Us